CHARGE association, hyper-immunoglobulin M syndrome, and conjunctival MALT lymphoma.
OBJECTIVE
To report a case of a 5-year-old child with CHARGE association and bilateral conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma treated with topical interferon-alpha.


METHODS
Case report.


RESULTS
A 5-year-old girl, diagnosed with nonclassical CHARGE association and hyper-immunoglobulin M (IgM) syndrome, was referred with a 2-month history of suspected purulent bilateral streptococcal conjunctivitis. Clinical symptoms did not resolve despite multiple antibiotic treatments, and her clinical course was attributed to underlying immunodeficiency. Biomicroscopy showed salmon-colored, nodular lesions occupying both fornices and caruncles. Inferior conjunctival biopsy was performed, and MALT lymphoma was diagnosed. Bilateral treatment was initiated with topical interferon-alpha, applied 3 times a day at a concentration of 5 x 10 U/m/d, for 4 months. Complete regression of symptoms and conjunctival lesions was achieved. No recurrences have been observed after 1-year follow-up.


CONCLUSIONS
We report the use of topical interferon-alpha as treatment for bilateral conjunctival MALT lymphoma in a young child with CHARGE association and hyper-IgM syndrome.
Fuentes-Páez
Graciana
G
Ocular Immunology and Uveitis Unit, Institute of Ophthalmobiology (IOBA), University of Valladolid and Hospital Clínico Universitario, Valladolid, Spain.
Saornil
M Antonia
MA
Herreras
José M
JM
Alonso-Ballesteros
María
M
Sánchez
Pilar Solis
PS
García-Tejeiro
Manuel
M
D000015:Abnormalities, Multiple; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D002754:Choanal Atresia / Q000150:complications; D003103:Coloboma / Q000150:complications; D003230:Conjunctival Neoplasms / Q000150:complications* / Q000188:drug therapy; D004423:Ear / Q000002:abnormalities; D005260:Female; D005836:Genitalia, Female / Q000002:abnormalities; D006130:Growth Disorders / Q000150:complications; D006801:Humans; D053306:Hyper-IgM Immunodeficiency Syndrome / Q000150:complications*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins